1. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin;Baselga;J Clin Oncol,2000
2. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852;Perez-Soler;J Clin Oncol,1994
3. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer;Modjtahedi;Br J Cancer,1996
4. Phase I trial of chimerized anti-epidermal growth factor receptor (Anti-EGFr) antibody in combinaiton with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies (meeting abstr);Ezekiel;Proc Am Soc Clin Oncol,1999
5. A Phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC) (meeting abstr);Mendelsohn;Proc Am Soc Clin Oncol,1999